Publicacións nas que colabora con Ana Isabel Rodríguez Pérez (67)

2024

  1. Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission

    npj Parkinson's Disease, Vol. 10, Núm. 1

  2. Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models

    Stem Cell Research and Therapy, Vol. 15, Núm. 1

  3. The role of the brain renin-angiotensin system in Parkinson´s disease

    Translational Neurodegeneration, Vol. 13, Núm. 1

2023

  1. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  2. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  3. Extracellular Vesicles and Their Renin–Angiotensin Cargo as a Link between Metabolic Syndrome and Parkinson’s Disease

    Antioxidants, Vol. 12, Núm. 12

  4. Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia

    Antioxidants, Vol. 12, Núm. 7

  5. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014

  6. The cannabinoid CB1 receptor interacts with the angiotensin AT2 receptor. Overexpression of AT2-CB1 receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats

    Experimental Neurology, Vol. 362

2022

  1. Angiotensin System Autoantibodies Correlate With Routine Prognostic Indicators for COVID-19 Severity

    Frontiers in Medicine, Vol. 9

  2. Angiotensin Type-1 Receptor Inhibition Reduces NLRP3 Inflammasome Upregulation Induced by Aging and Neurodegeneration in the Substantia Nigra of Male Rodents and Primary Mesencephalic Cultures

    Antioxidants, Vol. 11, Núm. 2

  3. Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease

    npj Parkinson's Disease, Vol. 8, Núm. 1

  4. Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment

    Biomedicines, Vol. 10, Núm. 2

  5. Microglial angiotensin type 2 receptors mediate sex-specific expression of inflammatory cytokines independently of circulating estrogen

    GLIA, Vol. 70, Núm. 12, pp. 2348-2360

  6. Parkinson's disease and diabetes mellitus: Common mechanisms and treatment repurposing

    Neural Regeneration Research, Vol. 17, Núm. 8, pp. 1652-1658

2021

  1. An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria

    Redox Biology, Vol. 46

  2. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19

    Journal of Autoimmunity, Vol. 122

  3. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists

    Frontiers in Neuroendocrinology, Vol. 62

  4. Estrogen Deficiency and Colonic Function: Surgical Menopause and Sex Differences in Angiotensin and Dopamine Receptor Interaction

    The journals of gerontology. Series A, Biological sciences and medical sciences, Vol. 76, Núm. 9, pp. 1533-1541

  5. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19

    Clinical Science, Vol. 135, Núm. 3, pp. 465-481